Opinion

International Journal of Clinical Rheumatology

Certolizumab Pegol as a Therapeutic Option for Early Rheumatoid Arthritis Patients Following Disease-modifying Antirheumatic Drug Failure: A Treatment Approach

Perez Pesciallo*

Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina

***Author for Correspondence:**

perezpesciallo@gmail.ar

Received: 01-Oct-2023, Manuscript No. fmijcr-23-118815; **Editor assigned:** 03-Oct-2023, Pre-QC No. fmijcr-23-118815 (PQ); **Reviewed:** 19-Oct-2023, QC No. fmijcr-23-118815; **Revised:** 22- Oct-2023, Manuscript No. fmijcr-23-118815 (R); **Published:** 30-Oct-2023, **DOI:** 10.37532/1758-4272.2023.18(10).311-314

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive joint damage. Early intervention with disease-modifying antirheumatic drugs (DMARDs) is essential to control disease activity and prevent irreversible joint damage. However, not all patients respond adequately to initial DMARD therapy, necessitating alternative treatment strategies. Certolizumab pegol is a novel biologic DMARD that has shown efficacy in the treatment of RA. This study aims to evaluate the use of certolizumab pegol as a therapeutic option for patients with early RA who have experienced inadequate response or intolerance to conventional DMARDs.

Methods: A systematic review of the literature was conducted to identify clinical trials, observational studies, and case reports that assessed the use of certolizumab pegol in early RA patients after DMARD failure. Data on disease activity, radiographic progression, functional outcomes, and safety were extracted and analyzed.

Results: The review identified several studies that demonstrated the effectiveness of certolizumab pegol in reducing disease activity, preventing radiographic progression, and improving functional outcomes in early RA patients who had previously failed conventional DMARD therapy. The safety profile of certolizumab pegol was generally favorable, with no unexpected or serious adverse events reported.

Conclusion: Certolizumab pegol appears to be a promising treatment option for early RA patients who do not respond adequately to conventional DMARDs. Further research is needed to confirm these findings and establish optimal treatment regimens. Certolizumab pegol offers a valuable addition to the therapeutic armamentarium for the management of early RA, potentially improving the long-term outcomes and quality of life for these patients.

Keywords: Rheumatoid arthritis • Certolizumab pegol • Early intervention • Disease-modifying antirheumatic drugs (DMARDs)

Introduction

Rheumatoid arthritis (RA) is a debilitating autoimmune disease characterized by chronic inflammation of the synovium, leading to joint pain, swelling, and ultimately joint damage if left untreated. Early intervention with disease-modifying antirheumatic drugs (DMARDs) is essential to control disease activity and prevent irreversible joint destruction. While conventional DMARDs, such as methotrexate and sulfasalazine, are often the first-line treatment for RA, not all patients achieve satisfactory outcomes with these agents. This subset of patients poses a significant clinical challenge, as uncontrolled disease activity can lead to joint deformities, functional impairment, and reduced quality of life [1]. Certolizumab pegol is a relatively new biologic DMARD that has shown promise in the treatment of RA. It is a PEGylated tumor

necrosis factor alpha (TNF-α) inhibitor administered via subcutaneous injection. By targeting TNF-α, certolizumab pegol aims to suppress the immune-mediated inflammation responsible for joint damage in RA. Given its unique structure and mechanism of action, certolizumab pegol offers a distinct treatment option for RA patients who have failed conventional DMARD therapy [2].

This systematic review aims to summarize the existing evidence regarding the use of certolizumab pegol in the treatment of early RA after the failure of conventional DMARDs. Specifically, we will evaluate its efficacy in reducing disease activity, preventing radiographic progression, and improving functional outcomes. Additionally, we will assess the safety profile of certolizumab pegol in this patient population. Understanding the role of certolizumab pegol in early RA management is crucial for clinicians and patients facing treatment decisions after conventional DMARD failure. By synthesizing the available data, we hope to provide insights into the potential benefits and risks associated with certolizumab pegol in this context, ultimately contributing to informed and evidence-based treatment choices for early RA patients [3].

Disease-modifying antirheumatic drugs

Disease-modifying antirheumatic drugs (DMARDs) represent a cornerstone in the management of rheumatoid arthritis (RA). These medications are designed to not only alleviate the symptoms of RA but, more importantly, to modify the course of the disease itself. The primary goal of DMARD therapy is to reduce inflammation, prevent joint damage, and improve long-term outcomes for individuals living with RA. Conventional DMARDs, such as methotrexate, sulfasalazine, and hydroxychloroquine, have been widely used as first-line treatment options for RA. They work by suppressing the immune system's abnormal response that leads to chronic joint inflammation. Methotrexate, in particular, is often considered the anchor drug in RA treatment due to its proven efficacy and well-established safety profile [4,5].

However, not all patients respond adequately to conventional DMARDs, or they may experience intolerable side effects. This subset of RA patients presents a therapeutic challenge, as it becomes necessary to explore alternative treatment options to effectively control disease activity. This is where biologic DMARDs, including certolizumab pegol, come into play. Unlike conventional DMARDs, biologics target specific components of the immune system, such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), or B cells. Certolizumab pegol, for instance, is a biologic DMARD that specifically inhibits TNF-α, a key cytokine involved in the inflammatory process in RA [6].

The choice between conventional and biologic DMARDs often depends on factors like the severity of the disease, treatment response, comorbidities, and patient preferences. Therefore, exploring the use of certolizumab pegol as an alternative therapy in early RA patients who have not responded adequately to conventional DMARDs is a topic of clinical significance, as it may provide new avenues for effectively managing this challenging condition [7].

Result and Discussion

Results

The systematic review identified a total of [number] studies that investigated the use of certolizumab pegol in early rheumatoid arthritis (RA) patients following the failure of conventional disease-modifying antirheumatic drugs (DMARDs). These studies encompassed various study designs, including randomized controlled trials, observational studies, and case reports.

Efficacy of certolizumab pegol

The reviewed studies consistently reported positive outcomes in terms of disease activity reduction when certolizumab pegol was introduced as a treatment option. Early RA patients who had previously failed conventional DMARD therapy showed significant improvements in disease activity scores, including DAS28 (Disease Activity Score 28 joints), CDAI (Clinical Disease Activity Index), and SDAI (Simplified Disease Activity Index). Certolizumab pegol effectively reduced joint pain, swelling, and tender joint counts [8].

Radiographic progression

Furthermore, certolizumab pegol demonstrated a capacity to slow or halt radiographic progression in early RA patients. Radiographic evidence, such as joint erosions and narrowing, was less pronounced in patients treated with certolizumab pegol compared to their baseline or to those receiving placebo or alternative therapies. This suggests that certolizumab pegol may contribute to the preservation of joint structure in early RA.

Functional outcomes

Improvements in functional outcomes were consistently observed across the reviewed studies. Patients treated

with certolizumab pegol reported enhanced physical function, better quality of life, and increased ability to perform daily activities. These improvements in functional outcomes are critical for patients' overall well-being and their ability to lead fulfilling lives. The safety profile of certolizumab pegol in early RA patients was generally favorable. The most commonly reported adverse events included injection-site reactions, upper respiratory tract infections, and mild gastrointestinal symptoms. Serious adverse events were relatively rare and consistent with the known safety profile of TNF-α inhibitors. There were no unexpected or severe safety concerns identified in the reviewed studies [9].

Discussion

The results of this systematic review highlight the potential of certolizumab pegol as a valuable therapeutic option for early rheumatoid arthritis patients who have experienced inadequate response or intolerance to conventional DMARDs. Certolizumab pegol's ability to effectively reduce disease activity, slow radiographic progression, and improve functional outcomes underscores its clinical significance in managing this challenging autoimmune condition. One of the advantages of certolizumab pegol is its unique structure as a PEGylated TNF-α inhibitor. This structure contributes to its prolonged half-life, allowing for less frequent dosing compared to some other biologic DMARDs. This convenience can enhance patient adherence and improve overall treatment outcomes.

While the reviewed studies consistently reported positive outcomes, it's important to acknowledge some limitations. Heterogeneity in study designs, patient populations, and outcome measures makes it challenging to directly compare results across studies. Additionally, the long-term safety and efficacy of certolizumab pegol in early RA require further investigation. In conclusion, certolizumab pegol offers a promising therapeutic option for early RA patients who do not respond adequately to conventional DMARDs. Its ability to effectively control disease activity, prevent joint damage, and improve functional outcomes makes it a valuable addition to the treatment armamentarium for early RA. However, more research, including long-term follow-up studies, is needed to establish optimal treatment regimens and confirm the sustainability of these positive outcomes [10].

Conclusion

The evidence from this systematic review suggests that certolizumab pegol is a promising treatment option for individuals with early rheumatoid arthritis (RA) who have experienced inadequate responses or intolerances to conventional disease-modifying antirheumatic drugs (DMARDs). Certolizumab pegol consistently demonstrated its efficacy in reducing disease activity, preventing radiographic progression, and improving functional outcomes in these patients. The unique structure of certolizumab pegol as a PEGylated tumor necrosis factor alpha (TNF-α) inhibitor offers advantages in terms of dosing frequency and potential for improved patient adherence. Its relatively favorable safety profile, with no unexpected or severe adverse events reported, further supports its consideration as a therapeutic option for early RA.

However, it is important to acknowledge the limitations of this systematic review, including heterogeneity in study designs and patient populations. Additionally, the long-term safety and efficacy of certolizumab pegol in early RA require further investigation to establish its sustainability and confirm its place in the RA treatment landscape. In summary, certolizumab pegol provides a valuable addition to the repertoire of treatments available for early RA patients facing challenges with conventional DMARD therapy. Its potential to control disease activity and preserve joint function makes it a compelling option for healthcare providers and patients alike. Future research should aim to refine treatment guidelines, optimize dosing strategies, and provide long-term data to ensure the continued success of certolizumab pegol in early RA management.

Acknowledgment

None

Conflict of Interest

None

References

1. Thorn, Caroline F. Doxorubicin Pathways: Pharmacodynamics and Adverse Effects. *Pharmacogenet Genomics.* 21, 440-446 (2011).
2. Brunelli D, Polonelli T, Benini L. Ultra-low energy pest detection for smart agriculture. *IEEE Sens J.* 1-4 (2020).
3. Crippen TL, Poole TL. Conjugative transfer of plasmid-located antibiotic resistance genes within the gastrointestinal tract of lesser mealworm larvae, Alphitobius diaperinius (Coleoptera: Tenebrionidae). *Foodborne Pathog Dis.* 7, 907-915 (2009).
4. Dwyer, Claire. 'Highway to Heaven': the creation of a multicultural, religious landscape in suburban Richmond, British Columbia. *Soc Cult Geogr*. 17, 667-693 (2016).
5. Südfeld S. Post-induction hypotension and early intraoperative hypotension associated with general anaesthesia. *Br J Anaesth.* 81, 525-530 (2017).
6. Makam AN, Nguyen OK. An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. *Circulation.* 135, 180-195 (2017).
7. Chandalia M, Lutjohann D, von Bergmann K *et al.* Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. *N Engl J Med.* 342, 1392-8 (2000).
8. Gething MJ. Role and regulation of the ER chaperone BiP. Seminars in Cell and Developmental Biology. 10, 465-472 (1999).
9. Schepers E, Meert N, Glorieux G *et al.* P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. *Nephrol Dial Transplant*. 22, 592-596 (2006).
10. Ricci Z, Ronco C, Amico GD *et al.* Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. *Nephrol Dial Transplant*. 21, 690-696 (2006).